Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies to Merge
Date:5/28/2008

Inc.

OncoGenex Technologies Inc. is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. OGX-427 has begun evaluation in Phase 1 clinical studies, while the third product candidate, OGX-225, has completed preclinical pharmacology studies. More information is available at http://www.OncoGenex.ca.

Safe Harbor

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the proposed merger between Sonus and OncoGenex. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, statements of expected synergies, the strength of the combined oncology product pipeline, the timing of clinical trials and development efforts, the results of clinical and pre-clinical studies, the timing of closing, execution of integration plans and management and organizational structure are all forward-looking statements. The potential risks and uncertainties include, among others, the possibility that the merger does not close or that the closing may be delayed, synergies and costs savings will not be achieved or that the companies are unable to su
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
2. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
3. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
4. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
5. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
6. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
7. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
8. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. Transdel Pharmaceuticals Closes $4 Million Financing
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Electronic circuits are based on electrons, but one of ... photonic circuits, i.e. circuits based on light (photons) instead ... to create a stream of single photons and control ... sorts of attempts to achieve this control, but now ... creating a steady stream of photons emitted one at ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/28/2014)... 28, 2014 SPIE Fellow Glenn Boreman, ... Optical Science and Director of the Center for Optoelectronics ... at Charlotte, and co-founder and Chairman of the Board ... the 2015 Vice President of SPIE, the international society ... Stahl announced recent election results at the Annual General ...
(Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... China, Jan. 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech ... acquisition of AppTec Laboratory,Services, Inc., a US-based ... industries. AppTec offers testing, contract research and,development, ... highly,differentiated, fully integrated platform., (Logo: ...
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be presenting at ... in New York on,Wednesday, February 6, 2008 at 1:00 ... Vice President, Finance and Chief Financial Officer of,Amylin Pharmaceuticals, ... presentation and breakout session will be webcast, and a,recording ...
... International,Inc. (Nasdaq: CHDX ) a leading independent ... the People,s Republic of China,announced that it intends ... ended December 31, 2007, on Friday, February 8, ... conference call on Friday,February 8, 2008 at 10:00 ...
Cached Biology Technology:WuXi PharmaTech Completes Acquisition of AppTec 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008 3
(Date:8/28/2014)... -- Privacy Advocate and Senior Staff Attorney at the Electronic ... lineup of biometric and mobile commerce experts set to ... in Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and Philippe ... of this year,s event is Mobility at the Crossroads ...
(Date:8/28/2014)... Aug. 28, 2014A new method for measuring and imaging ... doctors and researchers better understand how drug abuse affects ... and tissue engineering, and lead to better treatment options ... a team of researchers from Stony Brook University in ... Health, was published today in The Optical Society,s (OSA) ...
(Date:8/28/2014)... health risk to people with asthma according to a new ... Immunology . , By critically reviewing the findings from 17 ... the presence of several types of mould can lead to ... likelihood of developing the condition. , The research has been ... School and is the first time all of the information ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Indoor mold poses health risk to asthma sufferers 2
... NY, September 4, 2012The use of RNA in nanotechnology ... development of new therapeutic compounds. Key technical challenges remain, ... use of RNA molecules in nanotechnology approaches are presented ... , a peer-reviewed journal from Mary Ann Liebert, ...
... appliances in Spain are processed out of the Integrated ... of Salamanca exposes how many manufacturers are not registered ... According to the European directive on waste electrical ... the waste they generate during their activity until reaching ...
... fungal species, called , Hebelomagriseopruinatum , has now officially ... whose name can be translated into ,the grey-dewy tear ... mushroom-hunting tour headed by postdoc Jacob Heilman-Clausen from the ... 2009, postdoc Jacob Heilman-Clausen from the Center for Macroecology, ...
Cached Biology News:More than 70% of electronic waste management is uncontrolled 2More than 70% of electronic waste management is uncontrolled 3New Danish fungal species discovered 2
Request Info...
...
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: